Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study
Cancer Immunology, Immunotherapy · 18.11.2025 · 74 (12)
DOI: 10.1007/s00262-025-04228-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 18.11.2025. Verfasst von Qi Liu und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: The survival benefit of adding radiotherapy (RT) to immunochemotherapy (ICT) in patients with stage IVB esophageal squamous cell carcinoma (ESCC) confined to non-regional lymph node metastases remains uncertain. This study evaluated whether RT combined with first-line PD-1 inhibitor-based ICT improves outcomes. METHODS: In this multicenter retrospective cohort study, 343 patients with stage IVB ESCC (non-regional nodal metastases only; AJCC 8th edition) treated with PD-1 inhibitors plus chemotherapy between 2019 and 2021 were analyzed. Patients were stratified into RT (ICT + RT, n = 181) and non-RT (ICT alone, n = 162) groups. Propensity score matching (PSM) balanced baseline characteristics (age, sex, metastatic sites, etc.), yielding 125 matched pairs. RT (> 40 Gy to primary lesions) was delivered via IMRT/VMAT (median dose, 50.4 Gy). Primary endpoints were overall survival (OS) and progression-free survival (PFS). RESULTS: After PSM, the RT group showed significantly longer median OS (22.3 vs 14.9 months; HR 0.51, 95% CI 0.37-0.71; P < 0.001) and PFS (14.0 vs 6.1 months; HR 0.57, 95% CI 0.42-0.77; P < 0.001) versus non-RT. Sequential RT (post-induction ICT) conferred maximal OS benefit (median OS 29.2 vs 12.1 months; HR 0.38, P < 0.001). Exploratory analysis indicated that the most significant survival benefit was observed in patients receiving sequential RT targeting the primary tumor with or without metastatic nodes, rather than metastasis-directed RT alone. Grade 3-5 treatment-related adverse events were comparable between groups; however, RT was associated with significantly higher rates of grade 3-4 lymphopenia (15.2% vs 4.0%, p = 0.004) and esophagitis (11.2% vs 0%, p < 0.001). CONCLUSION: Adding RT to first-line ICT improves survival in stage IVB ESCC with non-regional nodal metastases, particularly when delivered sequentially to the primary tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, 270 Dong'an Road, Shanghai, 200032, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai Key Laboratory of Radiation Oncology, Shanghai, 200032, China.
- Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, China.
- RT Department of Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
- Department of Radiotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, 210000, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, Q., Chen, J., Xu, Y., Shen, W., Ye, J., Luo, H., Zhang, X., Liu, W., Xu, Y., Zhang, Y., Liu, A., Li, X., Ge, H., Wang, Q., Luo, H., Zhao, L., Xie, C., Lin, Q., Xie, C., …, & Zhao, K. (2025). Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study. Cancer Immunology, Immunotherapy, 74(12). https://doi.org/10.1007/s00262-025-04228-4
Vancouver
Liu Q, Chen J, Xu Y, Shen W, Ye J, Luo H, et al. Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study. Cancer Immunology, Immunotherapy. 2025;74(12). doi:10.1007/s00262-025-04228-4
BibTeX
@article{Liu2025,
author = {Liu, Qi and Chen, Junqiang and Xu, Yuanji and Shen, Wenbin and Ye, Jinjun and Luo, Honglei and Zhang, Xizhi and Liu, Wenyang and Xu, Yujin and Zhang, Yingying and Liu, Anwen and Li, Xiaopeng and Ge, Hong and Wang, Qifeng and Luo, Hui and Zhao, Lina and Xie, Conghua and Lin, Qin and Xie, Congying and Xiong, Jianping and Chen, Weiwei and Wang, Luhua and Zhao, Kuaile},
title = {Comparative analysis of immunochemotherapy with versus without radiation therapy for stage IVB esophageal squamous cell carcinoma confined to non-regional nodal metastases: a multicenter propensity score matching study},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {12},
doi = {10.1007/s00262-025-04228-4}
}
EUVIMED